Salarius Pharmaceuticals, Inc. (SLRX)
US — Healthcare Sector
Automate Your Wheel Strategy on SLRX
With Tiblio's Option Bot, you can configure your own wheel strategy including SLRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SLRX
- Rev/Share 0.0
- Book/Share 0.0372
- PB 29.0472
- Debt/Equity 1.8141
- CurrentRatio 1.4562
- ROIC -6.5294
- MktCap 2297473.0
- FreeCF/Share -2.6162
- PFCF -0.5278
- PE -0.3226
- Debt/Assets 0.048
- DivYield 0
- ROE -3.2414
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
SLRX
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer
Read More
About Salarius Pharmaceuticals, Inc. (SLRX)
- IPO Date 2015-01-29
- Website https://www.salariuspharma.com
- Industry Biotechnology
- CEO Mr. David J. Arthur M.B.A.
- Employees 2
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.